ASCO 2026 showcased early-stage cancer signals across multiple non-overlapping targets, including WEE1 inhibition and precision stratification approaches intended to refine which patients benefit. Aprea Therapeutics presented Phase 1 dose-escalation data for APR-1051, reporting partial responses in endometrial cancer within advanced solid tumors. Zentalis Pharmaceuticals highlighted early Phase Ib results for azenosertib combined with paclitaxel in platinum-resistant ovarian cancer, including an overall response rate of 39% and median progression-free survival of 7.3 months. The presentations reinforced ongoing competition to move checkpoint-adjacent strategies into more defined treatment settings earlier in development, particularly as investors scrutinize translational rationale and biomarker-driven design.